Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19.
作者信息
Kow Chia Siang, Hasan Syed S
机构信息
School of Pharmacy, Monash University Malaysia Bandar Sunway, Selangor, Malaysia.
School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.
出版信息
Am J Ther. 2021 Aug 6;28(5):e616-e619. doi: 10.1097/MJT.0000000000001441.
Abstract
摘要
相似文献
1
Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19.
Am J Ther. 2021 Aug 6;28(5):e616-e619. doi: 10.1097/MJT.0000000000001441.
2
Ivermectin in COVID-19: What do we know?
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1921-1922. doi: 10.1016/j.dsx.2020.09.027. Epub 2020 Sep 28.
3
Flawed ivermectin preprint highlights challenges of COVID drug studies.
Nature. 2021 Aug;596(7871):173-174. doi: 10.1038/d41586-021-02081-w.
4
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
Trials. 2020 Nov 24;21(1):965. doi: 10.1186/s13063-020-04813-1.
5
Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials.
Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102186. doi: 10.1016/j.dsx.2021.102186. Epub 2021 Jun 27.
6
Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19.
Br J Clin Pharmacol. 2021 Mar;87(3):1589-1590. doi: 10.1111/bcp.14476. Epub 2020 Jul 17.
7
Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
Trials. 2021 Apr 9;22(1):262. doi: 10.1186/s13063-021-05236-2.
8
Ivermectin in dermatology: why it 'mite' be useless against COVID-19.
Clin Exp Dermatol. 2021 Oct;46(7):1327-1328. doi: 10.1111/ced.14704. Epub 2021 Jun 26.
9
The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.
Nat Med. 2021 Nov;27(11):1853-1854. doi: 10.1038/s41591-021-01535-y.
10
Comparison of Trials Using Ivermectin for COVID-19 Between Regions With High and Low Prevalence of Strongyloidiasis: A Meta-analysis.
JAMA Netw Open. 2022 Mar 1;5(3):e223079. doi: 10.1001/jamanetworkopen.2022.3079.
引用本文的文献
1
Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 Patients.
Front Public Health. 2022 Feb 22;10:813378. doi: 10.3389/fpubh.2022.813378. eCollection 2022.
2
Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial.
JAMA. 2022 Feb 8;327(6):546-558. doi: 10.1001/jama.2022.0028.
3
Metformin in COVID-19: clinical trials are needed to prove its benefits.
Ir J Med Sci. 2022 Dec;191(6):2641-2642. doi: 10.1007/s11845-021-02869-9. Epub 2022 Jan 8.
本文引用的文献
1
Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial.
Infect Dis Rep. 2022 Mar 3;14(2):160-168. doi: 10.3390/idr14020020.
2
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet Respir Med. 2021 Dec;9(12):1419-1426. doi: 10.1016/S2213-2600(21)00435-5. Epub 2021 Oct 18.
3
Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India.
J Pharm Pharm Sci. 2021;24:343-350. doi: 10.18433/jpps32105.
4
The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review.
Expert Rev Anti Infect Ther. 2022 Feb;20(2):211-229. doi: 10.1080/14787210.2021.1949984. Epub 2021 Jul 29.
5
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines.
Am J Ther. 2021 Jun 21;28(4):e434-e460. doi: 10.1097/MJT.0000000000001402.
6
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
Lancet. 2021 May 29;397(10289):2049-2059. doi: 10.1016/S0140-6736(21)00897-7. Epub 2021 May 14.
7
Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.
BMC Infect Dis. 2021 May 4;21(1):411. doi: 10.1186/s12879-021-06104-9.
8
Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? A meta-analysis of randomized control trials.
Expert Rev Respir Med. 2021 Aug;15(8):1049-1055. doi: 10.1080/17476348.2021.1925546. Epub 2021 Jul 2.
9
The methodological quality of 176,620 randomized controlled trials published between 1966 and 2018 reveals a positive trend but also an urgent need for improvement.
PLoS Biol. 2021 Apr 19;19(4):e3001162. doi: 10.1371/journal.pbio.3001162. eCollection 2021 Apr.
10
The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis.
Pharmacol Rep. 2021 Oct;73(5):1473-1479. doi: 10.1007/s43440-021-00245-z. Epub 2021 Mar 29.
Zotero 插件